HCT for Relapsed or Refractory Follicular Lymphoma Leads to 5-Year Survival of 52%

Patients with relapsed/refractory follicular lymphoma (FL) can experience a 5-year progression-free survival (PFS) of 52%, according to the results of the largest FL study to date of 1,538 allogeneic hematopoietic cell transplant (HCT) recipients whose outcomes were reported to two major transplant registry databases. This retrospective study analyzed outcomes from transplants between 2001 and 2011 reported to EBMT (European Society for Blood and Marrow Transplantation; n=1,088) and CIBMTR (Center for International Blood and Marrow Transplant Research; n=450).

Median age was 51 years in both registries. The researchers noted that despite significant differences in patient characteristics and transplant strategies, long-term disease control was similar in both cohorts, with 5-year PFS of 52% in both cohorts, and 5-year overall survival of 61% and 62% in the CIBMTR and EBMT registries, respectively (p=0.69).

Sureda A, et al. Blood

Related Resource